Abstract: TH-PO0677
Combined Approach Using a Mouse Monoclonal Antibody and N-Acetylgalactosamine (GalNAc)-Specific Lectin for IgAN Monitoring
Session Information
- Glomerular Diseases: Immunopathogenesis and Targeted Therapeutics
November 06, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1401 Glomerular Diseases: Mechanisms, including Podocyte Biology
Authors
- Ka, Shuk-Man, National Defense Medical Center, Taipei City, Taiwan
- Chen, Ann, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
Background
IgA nephropathy (IgAN) is the common primary glomerulonephritis and a major cause of end-stage renal disease worldwide, but diagnosing IgAN requires an invasive procedure, which hinders early detection and monitoring of disease progression. Several reagents, including antibodies and lectins that recognize galactose-deficient (Gd) IgA1, the specific biomarker of IgAN, have been developed for a non-invasive and practical diagnostic strategy. However, their sensitivity and specificity have not yet met the required standards.
Methods
In present study, we used a newly identified anti-Gd-IgA1 antibody, ASK2, and a lectin, Crenomytilus grayanus lectin (CGL), with the aim of improving the development of early-stage IgAN diagnosis.
Results
ASK2 and CGL specifically distinguish Gd-IgA1 from normal IgA1 with intact O-glycans and show enhanced binding to serum and urine samples from patients with IgAN. They also bind to synthetic antigen-mimicking glycopeptides and recognize Gd-IgA1 in glomerular tissues, as demonstrated by immunofluorescence staining. The combined use of ASK2 and CGL markedly enhances the specificity and sensitivity of Gd-IgA1 detection in the sera of IgAN patients.
Conclusion
ASK2 and CGL represent promising tools for the non-invasive diagnosis of IgAN. By specifically targeting Gd-IgA1, this approach significantly improves diagnostic sensitivity and specificity, supporting its potential utility in the early detection and monitoring of IgAN progression.
Funding
- Government Support – Non-U.S.